Search results for "acute urinary retention"

showing 2 items of 2 documents

Predictive variables of spontaneous micturition recovery after acute urinary retention in men with benign prostatic enlargement: An observational pro…

2017

Objective: Acute urinary retention (AUR) is the sudden and painful inability to urinate spontaneously. AUR is one of the most significant complications of benign prostatic enlargement. The management of AUR is based on transurethral catheterization. Subsequent therapy is uncertain, but AUR seems to benefit from the use of alpha-blockers. The aim of this study was to evaluate the variables that could predict which patients would recover spontaneous micturition after trial without catheter. Methods: The present prospective observational study included men with AUR in an Italian tertiary care institute in 2016. Patients were catheterized and treated orally with fluoroquinolones, alpha-blockers…

Malemedicine.medical_specialtyNeurologymedia_common.quotation_subjectUrology030232 urology & nephrologyUrologyProstatic HyperplasiaUrinationUrinationSeverity of Illness IndexC-reactive protein03 medical and health sciences0302 clinical medicineProstatemedicineHumansProspective Studiesacute urinary retentionProspective cohort studymedia_commonAgedspontaneous micturition recoveryInternational Prostate Symptom ScorebiologyUrinary retentionbusiness.industryC-reactive proteinArea under the curveProstateOrgan SizeRecovery of FunctionMiddle AgedUrinary Retentionmedicine.anatomical_structureROC CurveNeurology030220 oncology & carcinogenesisArea Under CurveAcute Diseasebiology.proteinInternational Prostate Symptom Scoremedicine.symptombusinessUrinary Catheterization
researchProduct

Model‐based meta‐analysis of the time to first acute urinary retention or benign prostatic hyperplasia‐related surgery in patients with moderate or s…

2021

Aims Combination therapy of 5α‐reductase inhibitor and α‐blocker is a guideline‐endorsed therapeutic approach for patients with moderate‐to‐severe lower urinary tract symptoms or benign prostatic hyperplasia (LUTS/BPH) who are at risk of disease progression. We aimed to disentangle the contribution of clinical and demographic baseline characteristics affecting the risk of acute urinary retention or BPH‐related surgery (AUR/S) from the effect of treatment with drugs showing symptomatic and disease‐modifying properties. Methods A time‐to‐event model was developed using pooled data from patients (n = 10 238) enrolled into six clinical studies receiving placebo, tamsulosin, dutasteride or tamsu…

Malemedicine.medical_specialtydisease‐modifying propertiesCombination therapyProstatic HyperplasiaPlacebo030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinebaseline risk factorsLower urinary tract symptomsTamsulosinHumansMedicinePharmacology (medical)lower urinary tract symptoms030212 general & internal medicineacute urinary retentionPharmacologybenign prostatic hyperplasiadutasterideSulfonamidesbusiness.industryUrinary retentionHazard ratioOriginal ArticlesUrinary Retentionmedicine.diseaseDutasterideSurgeryTreatment OutcomechemistryAzasteroidstamsulosinOriginal ArticleDrug Therapy CombinationInternational Prostate Symptom Scoremedicine.symptombusinesstime‐to‐event modellingmedicine.drugBritish Journal of Clinical Pharmacology
researchProduct